Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials

Treatment for chronic immune thrombocytopenia (cITP) in children is largely limited to immunosuppressive agents. Thrombopoietin receptor agonists (TRAs) have been used to treat cITP in adults for over a decade. The objective of this integrated analysis was to examine the safety and efficacy of the TRA romiplostim in children with ITP.

[1]  A. Raj,et al.  Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia , 2019, Haematologica.

[2]  B. Chong,et al.  Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies , 2019, British journal of haematology.

[3]  J. Bussel,et al.  A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP) , 2016 .

[4]  P. Forbes,et al.  Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study , 2016, Pediatric blood & cancer.

[5]  A. Raj,et al.  Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.

[6]  J. Viallard,et al.  Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study , 2016, British journal of haematology.

[7]  J. Bussel,et al.  Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP) , 2014, Pediatric blood & cancer.

[8]  N. Cooper.  A review of the management of childhood immune thrombocytopenia: how can we provide an evidence‐based approach? , 2014, British journal of haematology.

[9]  Faki Osman Me.  Childhood immune thrombocytopenia: Clinical presentation and management , 2012 .

[10]  Mohamed El Faki Osman.  Childhood immune thrombocytopenia: Clinical presentation and management. , 2012, Sudanese journal of paediatrics.

[11]  Yow-Ming C Wang,et al.  A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. , 2011, Blood.

[12]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[13]  Mohsen Saleh Elalfy,et al.  Romiplostim in children with chronic refractory ITP: randomized placebo controlled study , 2011, Annals of Hematology.

[14]  D. Kuter,et al.  Thrombopoietin and platelet production in chronic immune thrombocytopenia. , 2009, Hematology/oncology clinics of North America.

[15]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[16]  J. Bussel,et al.  The pathogenesis of immune thrombocytopaenic purpura , 2006, British journal of haematology.

[17]  Mohsen Saleh Elalfy,et al.  Childhood ITP: 12 months follow‐up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS) , 2006, Pediatric blood & cancer.